HomeComparePCR vs GBDC

PCR vs GBDC: Dividend Comparison 2026

PCR yields 6.04% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.82M in total portfolio value
10 years
PCR
PCR
● Live price
6.04%
Share price
$19.19
Annual div
$1.16
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.8K
Annual income
$888.26
Full PCR calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — PCR vs GBDC

📍 GBDC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPCRGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PCR + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PCR pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PCR
Annual income on $10K today (after 15% tax)
$513.69/yr
After 10yr DRIP, annual income (after tax)
$755.02/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,982,368.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PCR + GBDC for your $10,000?

PCR: 50%GBDC: 50%
100% GBDC50/50100% PCR
Portfolio after 10yr
$10.44M
Annual income
$8,225,811.05/yr
Blended yield
78.79%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

PCR
No analyst data
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PCR buys
0
GBDC buys
0
No recent congressional trades found for PCR or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPCRGBDC
Forward yield6.04%11.86%
Annual dividend / share$1.16$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$29.8K$20.85M
Annual income after 10y$888.26$16,450,733.83
Total dividends collected$7.5K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: PCR vs GBDC ($10,000, DRIP)

YearPCR PortfolioPCR Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$11,304$604.34$12,492$1,791.70$1.2KGBDC
2$12,734$638.47$16,527$3,160.58$3.8KGBDC
3$14,298$672.18$23,588$5,904.90$9.3KGBDC
4$16,004$705.33$37,141$11,901.65$21.1KGBDC
5$17,862$737.85$66,205$26,463.38$48.3KGBDC
6$19,882$769.65$137,452$66,612.65$117.6KGBDC
7$22,074$800.64$342,372$195,298.53$320.3KGBDC
8$24,450$830.77$1,053,292$686,954.33$1.03MGBDC
9$27,022$859.99$4,111,439$2,984,416.95$4.08MGBDC
10$29,802$888.26$20,849,974$16,450,733.83$20.82MGBDC

PCR vs GBDC: Complete Analysis 2026

PCRStock

The Simplify VettaFi Private Credit Strategy ETF (PCR) seeks income and capital appreciation by investing in a private credit strategy plus a credit hedge derivatives strategy.The private credit strategy focuses on business development companies (BDCs) and publicly-traded closed end funds (CEFs) that primarily invest in the private credit sector.Credit hedging is primarily through a proprietary long/short hedge based on total return swaps of “quality” and “junk” equities.

Full PCR Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this PCR vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PCR vs SCHDPCR vs JEPIPCR vs OPCR vs KOPCR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.